VivoSim Labs (FRA:4OR) ROC (Joel Greenblatt) %: -1,255.81% (As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.71
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs ROC (Joel Greenblatt) %?

VivoSim Labs FRA:4OR 39 ROC (Joel Greenblatt) % is -1,255.81% as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.71. The stock has 4 warning signs investors should review. Among 1,325 Biotechnology companies, VivoSim Labs ranks better than 60.68% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. VivoSim Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,255.81%.

The historical rank and industry rank for VivoSim Labs's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:4OR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2424.5   Med: -1043.01   Max: -108.78
Current: -108.78

During the past 13 years, VivoSim Labs's highest ROC (Joel Greenblatt) % was -108.78%. The lowest was -2424.50%. And the median was -1043.01%.

FRA:4OR's ROC (Joel Greenblatt) % is ranked better than
60.68% of 1325 companies
in the Biotechnology industry
Industry Median: -297.52 vs FRA:4OR: -108.78

VivoSim Labs's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 33.40% per year.


VivoSim Labs  (FRA:4OR) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


VivoSim Labs ROC (Joel Greenblatt) % Related Terms


VivoSim Labs ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs ROC (Joel Greenblatt) % Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,428.52 -664.31 -663.63 -635.66 -152.62

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -919.12 1,966.06 -913.17 -980.54 -1,255.81

FRA:4OR vs SLXN, CDT, CLDI: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, VivoSim Labs's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's ROC (Joel Greenblatt) % falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.027 + 0 + 0.752) - (0.956 + 0 + 0.681)
=-0.858

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.028 + 0 + 0.605) - (1.073 + 0 + 0.586)
=-1.026

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of VivoSim Labs for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9.18/( ( (0.802 + max(-0.858, 0)) + (0.66 + max(-1.026, 0)) )/ 2 )
=-9.18/( ( 0.802 + 0.66 )/ 2 )
=-9.18/0.731
=-1,255.81 %

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -1,255.81% mean?
VivoSim Labs (FRA:4OR) has a ROC (Joel Greenblatt) % of -1,255.81% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #521 out of 1325 companies in the Biotechnology industry, placing it in the top 39.3%.
Is VivoSim Labs' ROC (Joel Greenblatt) % too high?
VivoSim Labs' current ROC (Joel Greenblatt) % is -1,255.81%. Based on the distribution chart, VivoSim Labs ranks #521 out of 1325 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' ROC (Joel Greenblatt) % compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #521 out of 1325 companies for ROC (Joel Greenblatt) %. This puts VivoSim Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current ROC (Joel Greenblatt) % is -1,255.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current ROC (Joel Greenblatt) % of -1,255.81%. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current ROC (Joel Greenblatt) % is -1,255.81%. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current ROC (Joel Greenblatt) % is -1,255.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.

Key valuation signals for FRA:4OR:

  • ROC (Joel Greenblatt) %: -1,255.81%
  • GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.71
GF Value